Breast Cancer
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
The PREFERABLE-EFFECT study found that supervised resistance and aerobic exercise were associated with reduced fatigue in patients with metastatic breast cancer.
Data from the DESTINY-Breast06 trial support the FDA breakthrough therapy designation for T-DXd in HR–positive, HER2-low, or HER2-ultralow breast cancer.
11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756
ByFatima Cardoso,Joyce O’Shaughnessy, MD,Heather McArthur, MD, MPH,Peter Schmid, MD,Javier Cortés, MD,Nadia Harbeck, MD, PhD,Melinda L. Telli, MD,David W. Cescon,Peter A. Fasching,Zhimin Shao,Delphine Loirat,Yeon Hee Park,Manuel Gonzalez Fernandez,Gábor Rubovszky,Seock-Ah Im,Rina Hui,Toshimi Takano,Fabrice André,Hiroyuki Yasojima,Zhenzhen Liu,Yu Ding,Liyi Jia,Vassiliki Karantza,Konstantinos Tryfonidis,Aditya Bardia, MD, MPH, FASCO
Phase 1 AC699-001 results evaluating the safety and efficacy of AC699 in patients with breast cancer subtypes support the Fast Track designation.
Findings from a population-based study suggest patients with POI may need genetic counseling regarding future risk of reproductive cancers.
Neoadjuvant/adjuvant sacituzumab govitecan showed encouraging intratumoral concentrations in patients with brain metastases as well as glioblastoma.
16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation
ByMatthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Gerald Batist,Javier Cortés, MD,Massimo Cristofanilli, MD,Giuseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Komal Jhaveri,Cynthia X. Ma, MD, PhD,Heather A. Parsons, MD, MPH,Hope S. Rugo, MD,Sarah L. Sammons,Daniel G. Stover,Chris Twelves, MD, FRCP,Aditya Bardia, MD, MPH, FASCO,Paul V. Plourde,David J. Portman,Senthil Damodaran
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Retrospective analysis found that cryoablation was associated with infrequent AEs and low recurrence rates among patients with breast cancer.
21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial
ByGabriel N. Hortobagyi, MD, FACP,Daniil Stroyakovskiy,Denise A. Yardley, MD,Chiun-Sheng Huang,Peter A. Fasching,John Crown,Aditya Bardia, MD, MPH, FASCO,Stephen Chia,Seock-Ah Im,Miguel Martin, MD, PhD,Sherene Loi, MD, PhD,Binghe Xu,Sara A. Hurvitz, MD,Carlos Barrios,Michael Untch, MD, PhD,Rebecca Moroose,Frances Visco,Federico Parnizari,Farhat Ghaznawi,Zheng Li,Sorcha Waters,Arunava Chakravartty,Dennis J. Slamon, MD, PhD
A holistic integration of time series and static data present in the learning approach can lead to improved understanding of breast cancer outcomes.
In terms of cancer detected per 1000 MRI exams, the AI scoring method was close to 4 times more efficient vs traditional breast density measures.
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Exploring The Impact of ADTs on Cardiac Risk in Prostate Cancer Treatment
3
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
4
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
5